Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company focusing on precision oncology treatments, announced today that it has entered into financial agreements to potentially increase its capital.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback